Clinical trials: Ranibizumab
Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
- Conditions
- Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT06190093
- Testing
- bevacizumab, ranibizumab
- Where
- 61 sites in United States
- Volunteers
- 400 people
- Sponsor
- Outlook Therapeutics, Inc.
Macular Degeneration
Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.
- Trial name
- NCT01134055
- Testing
- pazopanib eye drops, ranibizumab intravitreal injection
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 510 people
- Sponsor
- GlaxoSmithKline
Macular Degeneration
Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab
This study will measure antibody levels in the blood of people with bleeding or swelling in the retina who have or have not been treated with bevacizumab (Avastin[Trademark]or ranibizumab (Lucentis[Trademark]).
- Trial name
- NCT00605943
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Eye Institute (NEI)
Age-Related Macular Degeneration
Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab
To determine if patients treated early after diagnosis of wet age-related macular degeneration can return/maintain to their baseline pre-disease BCVA.
- Trial name
- COMPASS (NCT01402544)
- Testing
- ranibizumab
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Diego
Diabetic Macular Edema
Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
This study is a Phase I/II, multicenter, randomized, study of the efficacy and safety of ranibizumab injection monotherapy verses a duel therapy of 0.3mg ranibizumab combined with ultra wide, 200° field angiography guided pan…
- Trial name
- DAVE (NCT01552408)
- Testing
- 0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- David M. Brown, M.D.
Age Related Macular Degeneration
Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).
The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.
- Trial name
- MONET (NCT00713518)
- Testing
- 0.5 mg ranibizumab, 3 mg PF-04523655, 1 mg PF-04523655
- Where
- 31 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Quark Pharmaceuticals
Age-related Macular Degeneration (AMD)
Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
The purpose of this first-in-human study is to evaluate the safety and tolerability of single ascending doses of LMG324 to determine the maximum tolerated dose (MTD) in neovascular age-related macular degeneration (nvAMD)…
- Trial name
- NCT02398500
- Testing
- LMG324, Ranibizumab 0.5 mg
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Alcon Research
Sickle Cell Anemia, Retinopathy
Ranibizumab for Neovascularization in Sickle Cell Retinopathy
The purpose of this study is to determine the ocular and non-ocular safety of a single dose of ranibizumab in treating neovascularization secondary to sickle cell retinopathy.
- Trial name
- NCT00618644
- Testing
- Ranibizumab
- Where
- United States
- Sponsor
- Kresge Eye Institute
Age-related Macular Degeneration, Choroidal Neovascularization
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
- Trial name
- TREND (NCT01948830)
- Testing
- Ranibizumab 0.5mg
- Where
- 91 sites in Belgium, Chile and 17 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals
Eye Diseases, Macular Degeneration
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD
The purpose of this first-in-human study is to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of OPT-302 administered as monthly intravitreal injections for 3 months with and without Lucentis™ in patients with…
- Conditions
- Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration
- Trial name
- NCT02543229
- Testing
- OPT-302, Lucentis™
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Opthea Limited
Angioid Streaks
Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks
The purpose of this study is to determine whether injections of ranibizumab into the eye are safe and well tolerated when given to subjects in multiple doses.
- Trial name
- NCT01015495
- Testing
- ranibizumab
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Branch Retinal Vein Occlusion
Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT
The aim of the trial is to evaluate the efficacy and safety of intravitreal injections of ranibizumab for the treatment of macular edema due to BRVO if the re-treatment regimen is guided by morphological macular changes detected…
- Trial name
- RabOCT (NCT01968239)
- Testing
- Ranibizumab
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- University of Leipzig
Diabetic Macular Edema
Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment
In the prospective monocentric open label trial patients with diabetic macular edema will be treated with intravitreal injections of ranibizumab given for 3 months then with laser grid at month 4.
- Trial name
- NCT01823965
- Testing
- ranibizumab
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Poitiers University Hospital
Diabetic Macular Edema
Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema
Vitrectomy is required for removal of vitreous hemorrhage or retinal traction tissue in some patients with proliferative diabetic retinopathy. Post-vitrectomy macular edema may occur in these diabetic patients.
- Trial name
- NCT04089605
- Testing
- dexamethasone implant, Ranibizumab
- Where
- Taiwan
- Volunteers
- 48 people
- Sponsor
- Far Eastern Memorial Hospital
Coats Disease
Evaluation of Retinal and Vascular Features in Coats Disease After Intravitreal Injections of Ranibizumab
This study evaluates the retinal and vascular features in patients affected by Coats disease under the effects of Ranibizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography
- Trial name
- NCT04310631
- Testing
- Ranibizumab Injection
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Federico II University
Ophthalmopathy
Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)
To compare the clinical effectiveness of ranibizumab and combination of ranibizumab and triamcinolone for the treatment of macular oedema secondary to CRVO
- Trial name
- NCT04460001
- Testing
- Ranibizumab, triamcinolone acetate
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Choroidal Neovascularization, Age Related Macular Degeneration
SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
This investigator initiated pilot study is designed to investigate the efficacy and safety of SD-OCT-guided intravitreal ranibizumab treatment in choroidal neovascularization (CNV) due to myopia.
- Trial name
- NCT03409250
- Testing
- Ranibizumab, Lucentis
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vista Klinik
Macular Degeneration
Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis®) in Treat-and-extend at the CHU Brugmann.
Age-related macular degeneration (AMD) is a leading cause of blindness in people over 50 years old. Neovascular AMD, the most severe form and the most severe is characterized by the appearance, spread and growth of subretinal…
- Trial name
- NCT04988178
- Testing
- Data extraction from medical files
- Where
- Belgium
- Volunteers
- 34 people
- Sponsor
- Brugmann University Hospital
Choroidal Neovascularization (CNV)
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).
- Trial name
- NCT01840410
- Testing
- Ranibizumab
- Where
- 59 sites in Australia, Canada and 19 more
- Volunteers
- 183 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration
Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
The purpose of this study is to compare triple therapy using Photodynamic therapy, intravitreal Dexamethasone and intravitreal Ranibizumab injections versus monotherapy with intravitreal Ranibizumab alone for the treatment of…
- Trial name
- PDEX (NCT00390208)
- Testing
- ranibizumab, dexamethasone and verteporfin, Ranibizumab
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bay Area Retina Associates